Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$13.84 - $21.46 $1.89 Million - $2.93 Million
136,557 New
136,557 $2.89 Billion
Q4 2022

Feb 14, 2023

BUY
$10.28 - $14.78 $1.19 Million - $1.71 Million
115,899 New
115,899 $1.71 Million
Q3 2022

Nov 14, 2022

SELL
$6.57 - $24.88 $3,698 - $14,007
-563 Reduced 0.48%
116,128 $1.4 Million
Q2 2022

Aug 15, 2022

SELL
$5.75 - $7.74 $2,081 - $2,801
-362 Reduced 0.31%
116,691 $850,000
Q1 2022

May 11, 2022

SELL
$6.77 - $8.66 $17,216 - $22,022
-2,543 Reduced 2.13%
117,053 $798,000
Q4 2021

Feb 11, 2022

BUY
$8.5 - $12.0 $2,065 - $2,916
243 Added 0.2%
119,596 $1.03 Million
Q3 2021

Nov 12, 2021

BUY
$6.99 - $10.6 $201,871 - $306,128
28,880 Added 31.92%
119,353 $1.09 Million
Q2 2021

Aug 11, 2021

BUY
$6.68 - $11.07 $24,462 - $40,538
3,662 Added 4.22%
90,473 $840,000
Q1 2021

May 13, 2021

SELL
$6.26 - $11.03 $12,858 - $22,655
-2,054 Reduced 2.31%
86,811 $585,000
Q4 2020

Feb 09, 2021

BUY
$4.76 - $6.93 $18,368 - $26,742
3,859 Added 4.54%
88,865 $609,000
Q3 2020

Nov 12, 2020

SELL
$4.71 - $7.36 $58,036 - $90,689
-12,322 Reduced 12.66%
85,006 $475,000
Q2 2020

Aug 12, 2020

SELL
$3.61 - $6.47 $38,677 - $69,319
-10,714 Reduced 9.92%
97,328 $507,000
Q1 2020

May 06, 2020

SELL
$3.5 - $7.31 $32,655 - $68,202
-9,330 Reduced 7.95%
108,042 $412,000
Q4 2019

Feb 14, 2020

BUY
$4.6 - $7.88 $223,559 - $382,968
48,600 Added 70.67%
117,372 $913,000
Q3 2019

Nov 07, 2019

BUY
$4.89 - $8.0 $249,389 - $408,000
51,000 Added 286.97%
68,772 $386,000
Q1 2019

May 14, 2019

BUY
$4.75 - $7.1 $84,417 - $126,181
17,772 New
17,772 $89,000

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $1.06B
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.